Pediatric toxic epidermal necrolysis treated successfully with infliximab. Issue 3 (4th March 2019)

• Record Type: Journal Article
• Authors: Chafranska, Lana; Saunte, Ditte M.; Behrendt, Nille; Nygaard, Ulrikka; Christensen, Ryan J.; Sand, Carsten; Jemec, Gregor B.
• Is Part Of: Pediatric dermatology. Volume 36:Issue 3(2019)
• Page Start: 342
• Page End: 345
• Publication Date: 2019-03-04
• Subjects: infliximab -- mycoplasma pneumoniae -- Stevens‐Johnson syndrome -- toxic epidermal necrolysis -- toxic epidermal necrolysis, alpha inhibitor; Pediatric dermatology -- Periodicals; Children -- Diseases -- Periodicals; 618.925
• DOI: 10.1111/pde.13778
• Languages: English
• ISSNs: 0736-8046

Abstract

Abstract: Successful management of toxic epidermal necrolysis (TEN) with tumor necrosis factor‐α inhibitors has been described in adults. We present a case of a 7‐year‐old boy with infection‐associated TEN, diagnosed by typical clinical and histopathological features, most likely caused by Mycoplasma pneumoniae . Treatment with a single dose of infliximab 5 mg/kg intravenously on day 5 after the onset of symptoms was followed by cessation of all blister formation over 3 days and complete resolution within a week. Sequelae were mild, consisting of postinflammatory hyperpigmentation and dry eyes.